CompletedPhase 3NCT02579759
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
Studying Charcot-Marie-Tooth disease type 1A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pharnext S.C.A.
- Principal Investigator
- Shahram Attarian, MDCHU La Timone, Marseille, France
- Intervention
- PXT3003 dose 1(drug)
- Enrollment
- 323 enrolled
- Eligibility
- 16-65 years · All sexes
- Timeline
- 2015 – 2018
Study locations (30)
- Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, California, United States
- Hospital for Special Care, New Britain, New Britain, Connecticut, United States
- Department of Neurology, McKnight Brain Institute, Gainesville, Florida, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- University of Michigan Health System, Ann Arbor, Michigan, United States
- Department of Neurology, University of Minnesota, Minneapolis, Minnesota, United States
- Department of Neurology and Psichiatry, Saint Louis University, St Louis, Missouri, United States
- Peripheral Neuropathy Center, Neurological Institue Building, Columbia University Medical Center, New York, New York, United States
- Ohio State University, Columbus, Ohio, United States
- Saint Luke's Rehabilitation Institute, Spokane, Washington, United States
- Departement of Neurology, UZ Leuven, Leuven, Belgium
- University Hospital of Quebec, Québec, Quebec, Canada
- Centre de Référence des Maladies Neuromusculaires, Hôpital Swynghedauwl, CHU de Lille, Lille, France
- Centre de Référence des Neuropathies Périphériques Rares, Hôpital Dupuytren, CHU Limoges, Limoges, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02579759 on ClinicalTrials.govOther trials for Charcot-Marie-Tooth disease type 1A
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07140614A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.Novartis Pharmaceuticals
- RECRUITINGNANCT07049588Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A DiseaseAssistance Publique Hopitaux De Marseille
- RECRUITINGNCT07476365A Multi-omic Approach to the Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease (CMT1A)University Medical Center Goettingen
- RECRUITINGNCT06794489Longitudinal Biomarkers With Selected Outcome Measures In CMTUniversity Medical Center Goettingen
- ACTIVE NOT RECRUITINGNANCT02596191Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and BiomarkersAssistance Publique Hopitaux De Marseille